Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 years and over at the time of consent to the study.~* Diagnosis of SpA, as defined by the ASAS criteria for axial SpA~* Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of \> 1 month (for both NSAIDs combined) before the Screening visit.~* Active axial involvement defined by mini BASDAI~Exclusion Criteria:~* Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.~* Subjects who have received any previous treatment with etanercept or other TNFα inhibitors or biologic agents.~* Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: ACTIVE_COMPARATOR): Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
- etanercept-placebo (Type: PLACEBO_COMPARATOR): Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).